Genetic mutation in some Ashkenazi Jewish men may be linked to higher prostate cancer risk, study shows

BRCA-negative patients may still be high-risk for breast cancer, study finds

Women who test negative for BRCA gene mutations may still be at greater risk of developing breast cancer than the general population, according to a study led by investigators at Cedars-Sinai Medical Center, the University of Toronto, and the University of Sydney.

August 07, 2026

Vol.52 No.31

Clinical Roundup

Biobank of tumor models reveals cancers’ weak spots, Nature study finds

An open resource of patient-derived cancer models has enabled researchers to create the first large-scale map of the genes that cancers rely on to survive, offering new routes for research into better and less toxic treatments for patients.

August 07, 2026

Vol.52 No.31

Drugs & Targets

FDA approves Pluvicto for mHSPC

FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for patients with prostate-specific membrane antigen-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer, commonly known as metastatic hormone-sensitive prostate cancer.

August 07, 2026

Vol.52 No.31

Regulatory News

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”

In a video captioned “The High-T Department of War” and posted on X, Secretary of Defense Pete Hegseth announced that he was authorizing a screening program for troops to ensure “you have the right testosterone levels to operate at your absolute best.”

July 24, 2026

Vol.52 No.29

By Claire Marie Porter

Clinical Roundup

USC study shows how pieces of DNA that regulate gene expression drive prostate cancer

A study, which focused on the DNA switches of prostate cancer cells, reveals insights into enhancers that become active during cancer development and turn on genes linked to the disease. The study found that enhancers work cooperatively in 3D networks, rather than as isolated switches. Some enhancers function as “central hubs” that control many genes, while others play a supporting role. These findings could help with the development of targeted cancer therapies.

July 24, 2026

Vol.52 No.29

Clinical Roundup

Should lowest-risk prostate cancer still be called “cancer”? UCLA-led study suggests changing the name could save lives

A growing number of prostate cancer experts argue that calling the lowest-risk prostate cancer “cancer” does more harm than good. A UCLA-led study found removing the cancer label could dramatically reduce overtreatment and encourage more men to get screened, potentially leading to significantly fewer deaths from aggressive prostate cancer.

July 10, 2026

Vol.52 No.27

Genetic mutation in some Ashkenazi Jewish men may be linked to higher prostate cancer risk, study shows

YOU MAY BE INTERESTED IN

BRCA-negative patients may still be high-risk for breast cancer, study finds

Biobank of tumor models reveals cancers’ weak spots, Nature study finds

FDA approves Pluvicto for mHSPC

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”

USC study shows how pieces of DNA that regulate gene expression drive prostate cancer

Should lowest-risk prostate cancer still be called “cancer”? UCLA-led study suggests changing the name could save lives

Renew today!

Subscriber content

Never miss an issue!

Login

Genetic mutation in some Ashkenazi Jewish men may be linked to higher prostate cancer risk, study shows

YOU MAY BE INTERESTED IN

BRCA-negative patients may still be high-risk for breast cancer, study finds

Biobank of tumor models reveals cancers’ weak spots, Nature study finds

FDA approves Pluvicto for mHSPC

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warningsExperts caution the move amounts to a “huge, unregulated, natural experiment”

USC study shows how pieces of DNA that regulate gene expression drive prostate cancer

Should lowest-risk prostate cancer still be called “cancer”? UCLA-led study suggests changing the name could save lives

Never miss an issue!

Login

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”